Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Curasept is a commercially available topical antiseptic oral rinse developed and manufactured by Curasept S.p.A. Its primary active ingredient is 0.2% chlorhexidine digluconate, a broad-spectrum antimicrobial that targets bacterial cell membranes and disrupts biofilm matrices. A key feature of Curasept is its proprietary Anti Discoloration System (ADS), which incorporates ascorbic acid and sodium metabisulfite to minimize tooth staining and taste disturbances, common side effects of standard chlorhexidine products. The formulation also contains PVP-VA copolymer and Sodium DNA to support mucosal protection and regeneration. It is indicated for the treatment and management of periodontitis, gingivitis, dental plaque, peri-implantitis, and for use in post-periodontal surgical care.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Curasept (Curasept).